Predictors of poor response to oral propranolol in infantile hemangiomas
Archives de Pédiatrie · 2023
DOI: 10.1016/j.arcped.2023.06.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives de Pédiatrie, 2023. Verfasst von Fouzia Hali und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venerology, Ibn Rochd University Hospital of Casablanca, Morocco. Hauptthemen laut MEDLINE: Hemangioma, Skin Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Propranolol is the first-line treatment for infantile hemangiomas (IH). Cases of propranolol-resistant infantile hemangiomas are rarely reported. The purpose of our study was to investigate the predictive factors for poor response to propranolol. METHODS: A prospective analytical study was conducted between January 2014 and January 2022 including all patients with IH who received oral propranolol therapy at a dose of 2-3 mg/kg/day maintained for at least 6 months. RESULTS: A total of 135 patients with IH were treated with oral propranolol. Poor response was reported in 18 (13.4%) of the patients: 72% were girls and 28% were boys. Overall, 84% of the IH were mixed, and hemangiomas were multiple in three cases (16%), nasal tip hemangiomas accounted for four cases (22%), and 15 patients (83%) had segmental hemangiomas. There was no significant association between the age or sex of the children and type of response to treatment (p > 0.05). No significant association was found between the type of hemangioma and the therapeutic outcome as well as the recurrence after treatment discontinuation (p > 0.05). Multivariate logistic regression analysis revealed that nasal tip hemangiomas, multiple hemangiomas, and segmental hemangiomas were at greater risk of poor response to beta-blockers (p < 0.05). CONCLUSION: Poor response to propranolol therapy has rarely been reported in the literature. In our series, it was approximately 13.4%. To our knowledge, no previous publications have focused on the predictive factors of poor response to beta-blockers. However, the reported risk factors for recurrence are discontinuation of treatment before 12 months of age, mixed or deep type IH, and female gender. In our study, the predictive factors for poor response were multiple type IH, segmental type IH, and location on the nasal tip.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venerology, Ibn Rochd University Hospital of Casablanca, Morocco.
- Department of Dermatology and Venerology, Ibn Rochd University Hospital of Casablanca, Morocco. Electronic address: insaf.moubine10@gmail.com.
- Department of Medical Informatics, Ibn Rochd University Hospital of Casablanca, Morocco.
Zitieren
APA
Hali, F., Moubine, I., Berrami, H., Serhier, Z., Othmani, M. B., & Chiheb, S. (2023). Predictors of poor response to oral propranolol in infantile hemangiomas. Archives de Pédiatrie. https://doi.org/10.1016/j.arcped.2023.06.004
Vancouver
Hali F, Moubine I, Berrami H, Serhier Z, Othmani MB, Chiheb S. Predictors of poor response to oral propranolol in infantile hemangiomas. Archives de Pédiatrie. 2023. doi:10.1016/j.arcped.2023.06.004
BibTeX
@article{Hali2023,
author = {Hali, Fouzia and Moubine, Insaf and Berrami, Hind and Serhier, Zineb and Othmani, Mohammed Bennani and Chiheb, Soumiya},
title = {Predictors of poor response to oral propranolol in infantile hemangiomas},
journal = {Archives de Pédiatrie},
year = {2023},
doi = {10.1016/j.arcped.2023.06.004}
}
EUVIMED